SynthesisCancer research2012
An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.
Synthesis in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Bright side of the dark genome: antigens for next-gen cancer vaccines.Journal for immunotherapy of cancer · 2026Review
- Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion.Cancer immunology research · 2024Article
- Molecular and Circulating Biomarkers of Gastric Cancer.International journal of molecular sciences · 2022Review
- Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation.Oncology letters · 2020Article
- Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.Cell · 2020Article
- Role of Regenerating Islet-Derived Protein 3A in Gastrointestinal Cancer.Frontiers in oncology · 2019Review
- Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity.Oncotarget · 2018Article
- Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells.World journal of gastroenterology · 2018Review
- Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53 stability.Oncotarget · 2017Article
- CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B.Biochimie open · 2016Article
- Combination of OipA, BabA, and SabA as candidate biomarkers for predicting Helicobacter pylori-related gastric cancer.Scientific reports · 2016Article
- Emerging blood-based biomarkers for detection of gastric cancer.World journal of gastroenterology · 2015Review
- IQGAP3 promotes EGFR-ERK signaling and the growth and metastasis of lung cancer cells.PloS one · 2014Article
- Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.Cancer immunology research · 2013Article
- HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens.Oncoimmunology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
Abstract
Tumor-specific antigens (TSA) are central elements in the immune control of cancers. To systematically explore the TSA genome, we developed a computational technology called heterogeneous expression profile analysis (HEPA), which can identify genes relatively uniquely expressed in cancer cells in contrast to normal somatic tissues. Rating human genes by their HEPA score enriched for clinically useful TSA genes, nominating candidate targets whose tumor-specific expression was verified by reverse transcription PCR (RT-PCR). Coupled with HEPA, we designed a novel assay termed protein A/G-based reverse serological evaluation (PARSE) for quick detection of serum autoantibodies against an array of putative TSA genes. Remarkably, highly tumor-specific autoantibody responses against seven candidate targets were detected in 4% to 11% of patients, resulting in distinctive autoantibody signatures in lung and stomach cancers. Interrogation of a larger cohort of 149 patients and 123 healthy individuals validated the predictive value of the autoantibody signature for lung cancer. Together, our results establish an integrated technology to uncover a cancer-specific antigen genome offering a reservoir of novel immunologic and clinical targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.